Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma

Henrik Watz, Anne Kirsten, Frauke Pedersen, Torsten Goldmann, Florian Stellmacher, Mohib Uddin, Bengt Larsson, Gerhard Böttcher, Anna Malmgren, Marteen Kraan, Klaus Rabe
European Respiratory Journal 2016 48: PA4892; DOI: 10.1183/13993003.congress-2016.PA4892
Henrik Watz
1Pulmonary Research Institute at LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Kirsten
1Pulmonary Research Institute at LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frauke Pedersen
1Pulmonary Research Institute at LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Goldmann
2Institute of Pathology of the University Clinic Schleswig-Holstein, Campus Lübeck and the Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Stellmacher
2Institute of Pathology of the University Clinic Schleswig-Holstein, Campus Lübeck and the Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohib Uddin
3AstraZeneca, Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt Larsson
4AstraZeneca, Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Böttcher
4AstraZeneca, Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Malmgren
4AstraZeneca, Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marteen Kraan
4AstraZeneca, Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Rabe
5LungClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Modulating excessive airway neutrophilia might have beneficial effects in neutrophilic airway diseases. In humans the effects of CXCR2 antagonism are well characterized in peripheral blood and sputum, but there are no data on human bronchial mucosa.

Methods: We conducted an exploratory, single centre, open-label, non-controlled, pilot study with oral twice daily (BD) administration of 45 mg AZD5069 (90 mg/day) over 4 weeks in patients with moderate persistent neutrophilic asthma. Co-primary endpoints were neutrophil cell counts in bronchial mucosa obtained via bronchoscopic biopsy, induced sputum, and blood. Secondary endpoints included ligands of CXCR2 (IL-8, GRO-α) in sputum supernatant and serum (ClinicalTrials.gov Identifier:NCT01890148).

Results: 5 patients (mean age 47 years, 4 male patients; mean FEV1 83% pred., 65% neutrophils in sputum) were enrolled and 4 patients completed the study. There was a numeric decrease in neutrophil counts in mucosa, sputum and blood with a consecutive increase of IL-8 and GRO-α levels in sputum and serum. There was a total of 11 adverse events (AEs) of mild to moderate intensity with one AE being related to study treatment (low blood neutrophil counts resulting in withdrawal of the patient from study treatment). No serious AE occurred.

Conclusion: CXCR2-antagonism seems to simultaneously reduce the number of neutrophils in all investigated compartments, which suggests that the reduction of sputum neutrophilia is due to a reduced entry of neutrophils to the lung rather than a retention in the mucosa.

  • Inflammation
  • Bronchoscopy
  • Asthma - mechanism
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma
Henrik Watz, Anne Kirsten, Frauke Pedersen, Torsten Goldmann, Florian Stellmacher, Mohib Uddin, Bengt Larsson, Gerhard Böttcher, Anna Malmgren, Marteen Kraan, Klaus Rabe
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4892; DOI: 10.1183/13993003.congress-2016.PA4892

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma
Henrik Watz, Anne Kirsten, Frauke Pedersen, Torsten Goldmann, Florian Stellmacher, Mohib Uddin, Bengt Larsson, Gerhard Böttcher, Anna Malmgren, Marteen Kraan, Klaus Rabe
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4892; DOI: 10.1183/13993003.congress-2016.PA4892
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Monitoring local pulmonary cAMP levels: Combining precision cut lung slice (PCLS) and fluorescence resonance energy transfer (FRET) technologies in mice
  • Olodaterol attenuates bleomycin induced lung fibrosis in mice
  • Prostacyclin IP receptor activation blocks hyperosmolar-induced bronchoconstriction in isolated human small airways
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society